

Understanding Lung Cancer: Diagnosis, Types, and Treatment Options

Neeraj Saxena*

Department of Oncology, Temple University, School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, India

***Corresponding author:** Neeraj Saxena, Department of Oncology, Temple University, School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, India, E-mail: neeraj_s@gmail.com

Received: ng author:

ephasing the need for continued research to iprove outcoæs for patients with this de

lung cancer is a coplex and challenging disease characterized by the uncontrolled

small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC accounts for approximately 85% of all lung cancer cases, while SCLC makes up the remaining 15%. Each type has distinct characteristics, treatment approaches, and prognoses.

Non-Small cell lung cancer (NSCLC)

NSCLC is further divided into several subtypes, including:

Adenocarcinoma: is the most common subtype of NSCLC, often found in smokers and non-smokers alike. It typically originates in the outer regions of the lungs and can spread to other organs.

Squamous cell carcinoma: is subtype usually develops in the larger airways of the lungs and is strongly associated with smoking.

Large cell carcinoma: is a less common subtype of NSCLC that can appear in any part of the lung and tends to grow and spread quickly.

Small cell lung cancer (SCLC)

SCLC is less common but tends to grow and spread more rapidly than NSCLC. It is strongly linked to cigarette smoking and is often diagnosed at an advanced stage. This type of lung cancer typically responds well to chemotherapy but may have a poorer prognosis compared to NSCLC.

disciplines, are imperative in advancing early detection strategies, unraveling the molecular underpinnings of the disease, and ultimately, improving outcomes for patients affected by this devastating malignancy. Only through a comprehensive and integrated approach can we hope to mitigate the burden of lung cancer and usher in a new era of personalized, precision medicine.

References

1. Chen AC, Keleher A, Kedda MA, Spurdle AB, McMillan NA, et al. (2009) Human papillomavirus DNA detected in peripheral blood samples from healthy Australian male blood donors (PDF). J Med Virol 81: 1792-6.
2. Guan J, Bywaters SM, Brendle SA, Ashley RE, Makhov AM, et al. (2017) Cryoelectron Microscopy Maps of Human Papillomavirus 16 Reveal L2 Densities and Heparin Binding Site. Structure 25: 253-263.
3. Schiller JT, Day PM, Kines RC (2010) Current understanding of the mechanism of HPV infection. J Gynecol Oncol 118: 12-7.
4. Scheurer ME, Tortolero-Luna G, Adler-Storthz K (2005) Human papillomavirus infection: biology, epidemiology, and prevention. Int J Gynecol Cancer 15: 727-46.
5. Meyers J, Ryndock E, Conway MJ, Meyers C, Robison R (2014) Susceptibility of high-risk human papillomavirus type 16 to clinical disinfectants. J Antimicrob